ClinicalTrials.gg
CompletedNCT03739528LEADER7Updated Aug 18, 2020Results posted

Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery

A Phase 3 interventional study of Levofloxacin + dexamethasone followed by dexamethasone and Tobramycin + Dexamethasone in Cataract, sponsored by NTC srl. Completed at 57 sites in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-08-18.

Sponsored by NTC srl · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
808
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
2nd of 34
808 · median 50
Started
2018
with 2 others
Phase 3
9 of 34
1 open now
Registered
8th of 34
by date
Lead sponsor
2 of 34
NTC srl

Among the 34 studies testing dexamethasone in Cataract, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 8th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the non-inferiority of the study treatment (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone vs. standard treatment in the prevention and treatment of postoperative ocular inflammation and prevention of infection.

Read the detailed description

In clinical practice, topical treatment following cataract surgery is frequently administered using a combination between an antibiotic and a corticosteroid to promote patient adherence to therapy and to obtain both prevention of infection and treatment of post-surgical inflammation.

The combination of tobramycin and dexamethasone is among the most widely used combinations, however, treatment duration and the need for tapering posology over several weeks may favour the development of bacterial resistance. The study treatment associating a broad-spectrum antibiotic with a highly effective corticosteroid that can be used for a short period of time (one week) is therefore of considerable interest.

The aim of this study is to evaluate the non-inferiority of the study treatment, used for a limited period of time and followed by dexamethasone alone, compared to standard treatment in preventing and treating ocular inflammation and in preventing post-operative infection while limiting the emergence of antibiotic resistance.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria prior to surgery:

  1. Signed written
  2. Male or female, age ≥40 years
  3. Scheduled senile or presenile cataract surgery
  4. Willing to interrupt the use of contact lenses for the entire duration of the study
  5. Able and willing to follow study procedures
  6. Female patients must be , surgically sterile or must agree to use an effective method of

    Inclusion criteria following surgery:

  7. Surgery completed without complications

Exclusion Criteria:

  1. Ocular conditions that at the discretion of the Investigator may interfere with the efficacy and/or safety evaluations
  2. Patients undergoing bilateral cataract surgery
  3. Patients under treatment with prostaglandin analogues or intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs
  4. Systemic diseases that may interfere with the results of the study
  5. Any condition that could interfere with correct instillation of eye drops
  6. Ocular surgery in the study eye (including laser surgery) in the 3 months before screening
  7. Monocular patients
  8. Visual Acuity \< 20/80 of the contralateral eye measured as ETDRS or Snellen
  9. to ocular treatment with Tobradex®, Maxidex® or levofloxacin/dexamethasone
  10. to the study product or its
  11. Participation in other clinical studies within at least 5 half-lives of the Medicinal Product (IMP) used in the previous studies
  12. Pregnancy or breastfeeding
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
808 participants (actual)

Study arms

  • Experimental
    Levofloxacin + Dexamethasone followed by dexamethasone

    Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).

    Drug: Levofloxacin + dexamethasone followed by dexamethasone

  • Active comparator
    Tobramycin + dexamethasone

    Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).

    Drug: Tobramycin + Dexamethasone

Interventions

  • DrugLevofloxacin + dexamethasone followed by dexamethasone

    Drug pages: Levofloxacin · Dexamethasone

    Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.

    Also known as: Levofloxacin + dexamethasone followed by Maxidex

  • DrugTobramycin + Dexamethasone

    Drug pages: Tobramycin · Dexamethasone

    Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.

    Also known as: Tobradex

06

What researchers measure

Primary outcomes

  1. Number of Participants Without Signs of Anterior Chamber Inflammation

    The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS \> - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.

    Time frame: Day 15

Secondary outcomes

  1. Number of Participants With Endophthalmitis

    The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.

    Time frame: Day 4, 8, 15

  2. Number of Participants Without Signs of Anterior Ocular Chamber Inflammation

    Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).

    Time frame: Day 0 (screening), 4, 8

  3. Conjunctival Hyperemia

    Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).

    Time frame: Day 4, 8, 15

  4. Total Ocular Symptoms Score (TOSS)

    The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

    Time frame: Day 4, 8, 15

  5. Ocular Pain/Discomfort: 4-point Scale

    Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).

    Time frame: Day 4, 8, 15

  6. Use of Rescue Therapy

    All rescue therapy used following cataract surgery is to be reported at all visits.

    Time frame: During all the treatment until day 15

Other outcomes

  1. Intraocular Pressure (IOP)

    IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.

    Time frame: At day 0 (screening) and at day 4, 8, 15

  2. Visual Acuity

    Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction. Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision. Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.

    Time frame: At day 0 (screening) and at day 15

  3. Adverse Events

    Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.

    Time frame: During all the treatment until day 15

  4. Global Evaluation of Local Tolerability

    Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.

    Time frame: Day 4, 8, 15

  5. Burning, Stinging, Blurred Vision

    Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

    Time frame: Day 4, 8, 15

  6. Assessment of Patient Diary (Compliance)

    Treatment compliance is derived from the number of instillations each day during the study treatment exposure

    Time frame: Day 15

07

Results

Posted Aug 18, 2020

Participant flow

Study period: * Date of first enrolment: 03.09.2018 * Date study finalized (LPLV): 19.12.2018 Study centers: * 42 centers in Italy * 4 centers in Spain * 4 centers in Russia * 1 center in Germany

Participant flow — Overall Study
MilestoneLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Started403405
Received at least one treatment395393
Completed388388
Not completed1517
Withdrew: Not treated812
Withdrew: Treatment and study discontinued62
Withdrew: Treatment discontinued + study completed13

Outcome measures

PrimaryNumber of Participants Without Signs of Anterior Chamber Inflammation

The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS \> - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.

Time frame:
Day 15
Reported as:
Count of participants · Participants
Number of Participants Without Signs of Anterior Chamber Inflammation
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Number of participants without signs376373
Number of participants with signs1920
SecondaryNumber of Participants With Endophthalmitis

The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.

Time frame:
Day 4, 8, 15
Reported as:
Count of participants · Participants
Number of Participants With Endophthalmitis
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 3 - Day 4: no diagnosis of endophthalmitis393393
Visit 4 - Day 8: no diagnosis of endophthalmitis391393
Visit 5 - Day 15: no diagnosis of endophthalmitis389391
SecondaryNumber of Participants Without Signs of Anterior Ocular Chamber Inflammation

Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).

Time frame:
Day 0 (screening), 4, 8
Reported as:
Count of participants · Participants
Number of Participants Without Signs of Anterior Ocular Chamber Inflammation
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 1 - Screening — Number of participants without signs395393
Visit 1 - Screening — Number of participants with signs00
Visit 3 - Day 4 — Number of participants without signs289302
Visit 3 - Day 4 — Number of participants with signs10691
Visit 4 - Day 8 — Number of participants without signs338341
Visit 4 - Day 8 — Number of participants with signs5752
SecondaryConjunctival Hyperemia

Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).

Time frame:
Day 4, 8, 15
Reported as:
Count of participants · Participants
Conjunctival Hyperemia
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 3 - Day 4 — Score=0337323
Visit 3 - Day 4 — Score>05870
Visit 4 - Day 8 — Score=0348358
Visit 4 - Day 8 — Score>04735
Visit 5 - Day 15 — Score=0371375
Visit 5 - Day 15 — Score>02418
SecondaryTotal Ocular Symptoms Score (TOSS)

The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

Time frame:
Day 4, 8, 15
Reported as:
Mean · score on a scale
Total Ocular Symptoms Score (TOSS)
score on a scaleLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 3 - Day 40.29 ± 0.630.37 ± 0.73
Visit 4 - Day 80.28 ± 0.670.26 ± 0.62
Visit 5 - Day 150.17 ± 0.490.17 ± 0.59
SecondaryOcular Pain/Discomfort: 4-point Scale

Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).

Time frame:
Day 4, 8, 15
Reported as:
Count of participants · Participants
Ocular Pain/Discomfort: 4-point Scale
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 3 - Day 4: Presence/absence of ocular pain — Score=0360361
Visit 3 - Day 4: Presence/absence of ocular pain — Score>03532
Visit 4 - Day 8: Presence/absence of ocular pain — Score=0366366
Visit 4 - Day 8: Presence/absence of ocular pain — Score>02927
Visit 5 - Day 15: Presence/absence of ocular pain — Score=0377373
Visit 5 - Day 15: Presence/absence of ocular pain — Score>01820
SecondaryUse of Rescue Therapy

All rescue therapy used following cataract surgery is to be reported at all visits.

Time frame:
During all the treatment until day 15
Reported as:
Count of participants · Participants
Use of Rescue Therapy
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Patients with rescue therapy392392
Patients with no rescue therapy31
Other pre-specifiedIntraocular Pressure (IOP)

IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.

Time frame:
At day 0 (screening) and at day 4, 8, 15
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 1 - Screening15.16 ± 2.4815.12 ± 2.41
Visit 3 - Day 414.26 ± 2.7314.49 ± 2.81
Visit 4 - Day 814.29 ± 2.5114.45 ± 3.03
Visit 5 - Day 1514.45 ± 2.6514.37 ± 2.47
Other pre-specifiedVisual Acuity

Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction. Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision. Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.

Time frame:
At day 0 (screening) and at day 15
Reported as:
Mean · decimal score
Visual Acuity
decimal scoreLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 1 - Screening0.41 ± 0.230.41 ± 0.26
Visit 5 - Day 150.88 ± 0.190.89 ± 0.17
Other pre-specifiedAdverse Events

Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.

Time frame:
During all the treatment until day 15
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Patients with TEAEs5651
Patients with serious TEAEs42
Patients with TEAEs suspected to be study related2626
Patients with TEAEs leading to discontinuation43
Patients with fatal TEAEs10
Patients with severe TEAEs30
Other pre-specifiedGlobal Evaluation of Local Tolerability

Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.

Time frame:
Day 4, 8, 15
Reported as:
Mean · score on a scale
Global Evaluation of Local Tolerability
score on a scaleLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Visit 3 - Day 40.03 ± 0.210.01 ± 0.09
Visit 4 - Day 80.01 ± 0.110.03 ± 0.19
Visit 5 - Day 150.02 ± 0.150.02 ± 0.13
Other pre-specifiedBurning, Stinging, Blurred Vision

Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.

Time frame:
Day 4, 8, 15
Reported as:
Mean · score on a scale
Burning, Stinging, Blurred Vision
score on a scaleLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
Burning: visit 3 - day 40.08 ± 0.270.09 ± 0.29
Burning: visit 4 - day 80.06 ± 0.240.11 ± 0.35
Burning: visit 5 - day 150.07 ± 0.290.07 ± 0.27
Stinging: visit 3 - day 40.05 ± 0.230.04 ± 0.20
Stinging: visit 4 - day 80.07 ± 0.290.07 ± 0.26
Stinging: visit 5 - day 150.06 ± 0.260.04 ± 0.20
Blurred vision: visit 3 - day 40.06 ± 0.270.05 ± 0.23
Blurred vision: visit 4 - day 80.06 ± 0.250.04 ± 0.22
Blurred vision: visit 5 - day 150.03 ± 0.200.01 ± 0.11
Other pre-specifiedAssessment of Patient Diary (Compliance)

Treatment compliance is derived from the number of instillations each day during the study treatment exposure

Time frame:
Day 15
Reported as:
Count of participants · Participants
Assessment of Patient Diary (Compliance)
ParticipantsLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
No missed dose332332
One missed dose per day or three missed doses per5957
> 1 missed dose per day or > 3 missed doses per we44

Adverse events

Collected over From baseline to the end of the treatment, corresponding to 15 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levofloxacin + Dexamethasone Followed by Dexamethasone1/395 (0.3%)4/388 (1%)0/395 (0%)
Tobramycin + Dexamethasone0/393 (0%)2/388 (0.5%)0/393 (0%)
Most frequent serious events
Most frequent serious events
EventLevofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + Dexamethasone
FallInjury, poisoning and procedural complications2/3881/388
Myocardial InfarctionCardiac disorders1/3881/388
Retinal DetachmentEye disorders1/3880/388

Baseline characteristics

The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)

Age, Categorical
Age, Categorical(Participants)Levofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + DexamethasoneTotal
<=18 years000
Between 18 and 65 years7071141
>=65 years325322647
Age, Continuous
Age, Continuous(years)Levofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + DexamethasoneTotal
Mean72.12 ± 8.5571.84 ± 8.6471.98 ± 8.59
Sex: Female, Male
Sex: Female, Male(Participants)Levofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + DexamethasoneTotal
Female229239468
Male166154320
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levofloxacin + Dexamethasone Followed by DexamethasoneTobramycin + DexamethasoneTotal
American Indian or Alaska Native101
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American000
White393391784
More than one race000
Unknown or Not Reported000
08

Study locations

57 sites
  • A.O.U. Osp. Riuniti Umberto I - G.M. Lancisi - G. Salesi - Università degli Studi di Ancona
    Ancona, AN 60126, Italy
  • Ospedale della Murgia "Fabio Perinei" di Altamura
    Altamura, BA 70022, Italy
  • A.O.U. Policlinico Consorziale di Bari
    Bari, BA 70125, Italy
  • ASL Bari - Ospedale "Di Venere" - Carbonara di Bari
    Bari, BA 70131, Italy
  • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni di Bergamo
    Bergamo, BG 24125, Italy
  • A.O.U. di Bologna - Policlinico S. Orsola-Malpighi di Bologna
    Bologna, BO 40138, Italy
  • Policlinico S. Orsola-Malpighi di Bologna
    Bologna, BO 40138, Italy
  • ASST degli Spedali Civili di Brescia - P.O. Spedali Civili di Brescia
    Brescia, BS 25123, Italy
  • ASST Franciacorta - P.O. di Chiari
    Chiari, BS 25032, Italy
  • P.O. Ospedale Clinicizzato SS. Annunziata di Chieti
    Chieti, CH 66100, Italy
  • Ospedale Valduce di Como
    Como, CO 22100, Italy
  • A.O.U. Policlinico Vittorio Emanuele - P.O. Gaspare Rodolico - Università degli Studi di Catania
    Catania, CT 95123, Italy
  • Policlinico G.B. Morgagni di Catania - Casa di Cura s.r.l.
    Catania, CT 95125, Italy
  • A.O. Mater Domini di Catanzaro - Università degli Studi Magna Graecia di Catanzaro
    Catanzaro, CZ 88100, Italy
  • IRCCS Casa Sollievo della Sofferenza di San Giovanni Rotondo
    San Giovanni Rotondo, FG 71013, Italy
  • A.O.U. Careggi di Firenze
    Firenze, FI 50139, Italy
  • IRCCS Ospedale Policlinico San Martino di Genova
    Genova, GE 16132, Italy
  • Ospedale Policlinico San Martino - Università degli Studi di Genova
    Genova, GE 16132, Italy
  • Fatebenefratelli - Ospedale "Sacra Famiglia" di Erba
    Erba, LC 22036, Italy
  • Az. USL Toscana Nord Ovest - Ospedale della Versilia
    Lido Di Camaiore, LU 55049, Italy
  • AUSL Toscana Nord Ovest - P.O. San Luca di Lucca
    San Filippo, LU 56123, Italy
  • A.O.U. Policlinico "G. Martino" di Messina
    Messina, ME 98124, Italy
  • ASP di Messina - P.O. "Giuseppe Fogliani" di Milazzo
    Milazzo, ME 98057, Italy
  • ASST Ovest Milanese - Ospedale Civile di Legnano
    Legnano, MI 20025, Italy
  • IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
    Milano, MI 20122, Italy
  • Gruppo Multimedica - Ospedale San Giuseppe di Milano
    Milano, MI 20123, Italy
  • Ospedale San Raffaele IRCCS S.r.l.
    Milano, MI 20132, Italy
  • ASST Fatebenefratelli Sacco - Università degli Studi di Milano - Ospedale L. Sacco
    Milano, MI 20157, Italy
  • IRCCS Istituto Clinico Humanitas di Rozzano
    Rozzano, MI 20089, Italy
  • ASST di Melegnano e della Martesana - Ospedale di Vizzolo Predabissi
    Vizzolo Predabissi, MI 20077, Italy
  • A.O.U. Policlinico di Modena - Università degli Studi di Modena e Reggio Emilia
    Modena, MO 41125, Italy
  • Ospedale di Sassuolo
    Sassuolo, MO 41049, Italy
  • Centro Polispecialistico Monterosso di Carrara
    Carrara, MS 54033, Italy
  • A.O.U. Policlinico "P. Giaccone" di Palermo
    Palermo, PA 90127, Italy
  • A.O. "Ospedali Riuniti Villa Sofia-Cervello" di Palermo - P.O. "Villa Sofia" di Palermo
    Palermo, PA 90146, Italy
  • AUSL di Piacenza - Ospedale "Guglielmo da Saliceto" di Piacenza
    Piacenza, PC Piacenza, Italy
  • Az. ULSS 6 Euganea - Ospedali Riuniti Padova Sud - Ospedale Madre Teresa di Calcutta-Schiavonia
    Monselice, PD) 35043, Italy
  • Az. ULSS 6 Euganea - Ospedale S. Antonio - Centro Oculistico San Paolo di Padova
    Padova, PD 35100, Italy
  • A.O. di Perugia - Ospedale S. Maria della Misericordia di Perugia
    Perugia, PG 06156, Italy
  • Fondazione IRCCS Policlinico S. Matteo - Università degli Studi di Pavia
    Pavia, PV 27100, Italy
  • Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli di Reggio Calabria
    Reggio Calabria, RC 89124, Italy
  • Policlinico Universitario Campus Bio-medico di Roma
    Roma, RM 00128, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Roma, RM 00133, Italy
  • A.O.U. Sant'Andrea di Roma
    Roma, RM 00189, Italy
  • IRCCS Fondazione G.B. Bietti di Roma
    Roma, RM 00198, Italy
  • ASL Roma 4 - Ospedale San Paolo di Civitavecchia
    Civitavecchia, RN 00053, Italy
  • Az. ULSS 5 Polesana - Ospedale "Santa Maria della Misericordia"
    Rovigo, RO 45100, Italy
  • A.O.U Città della Salute e della Scienza di Torino - Ospedale Molinette
    Torino, TO 10126, Italy
  • Az. Sanitaria Universitaria Integrata di Trieste - Ospedali Riuniti di Trieste - Ospedale Maggiore
    Trieste, TS 34129, Italy
  • Az. ULSS 2 Marca Trevigiana - Ospedale di Treviso
    Treviso, TV 31100, Italy
  • Az. Sanitaria Universitaria Integrata di Udine - P.O. Universitario "Santa Maria della Misericordia" diUdine
    Udine, UD 33100, Italy
  • Az. ULSS 7 Pedemontana - Ospedale San Bassiano di Bassano del Grappa
    Bassano Del Grappa, VI 36061, Italy
  • Ospedale Sacro Cuore - Don Calabria di Negrar
    Negrar, VR 37024, Italy
  • A.O.U. Integrata di Verona - Ospedale Borgo Roma
    Verona, VR 37134, Italy
  • Az. Osp. di Rilievo Nazionale "A. Cardarelli" di Napoli
    Napoli, 80131, Italy
  • A.O.U. "Maggiore della Carità" di Novara
    Novara, 28100, Italy
  • A.O.U. Senese - Università degli Studi di Siena
    Siena, 53100, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Dec 2018, 3 months.

Results were first posted in Aug 2020, 1 year 7 months after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 14, 2018
StartActual
Sep 3, 2018
Primary completionActual
Dec 19, 2018
CompletionActual
Dec 19, 2018
Results first posted
Aug 18, 2020
Last update
Aug 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03739528
Lead sponsor
NTC srl
Responsible party
Sponsor
First posted
Nov 14, 2018
Start date
Sep 3, 2018
Primary completion
Dec 19, 2018
Completion
Dec 19, 2018
Results posted
Aug 18, 2020
Last update
Aug 18, 2020

Study contacts

Francesco Bandello, Prof.
principal investigator · Ospedale San Raffaele IRCCS S.r.l.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levofloxacin · Dexamethasone

Start the discussion